Madrigal Pharmaceuticals shares rise 1.45% premarket after signing a $2 billion-plus deal with CSPC for liver disease treatment.

Madrigal Pharmaceuticals, Inc. rose 1.45% in premarket trading, driven by the company's recent licensing agreements. Madrigal signed an exclusive global license agreement for a potential liver disease treatment with CSPC Pharmaceutical Group Limited, valued at over $2 billion. Additionally, the companies have partnered to develop an anti-obesity and diabetes drug, further bolstering Madrigal's pipeline and market potential.